TIDMPRTC
PureTech Health PLC
11 April 2019
11 April 2019
PureTech Health Affiliate Akili Appoints Chief Financial Officer
and General Counsel to Leadership Team
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that its affiliate, Akili Interactive, has appointed Santosh
Shanbhag as chief financial officer and Jacqueline Studer as senior
vice president and general counsel.
Shanbhag is a senior financial executive with 20 years of
experience. Most recently, he comes from Vertex Pharmaceuticals,
where he served as vice president and head of international finance
and accounting and was responsible for the company's international
business operations for key markets.
Studer brings decades of experience providing legal strategy to
large and emerging growth healthcare companies. She was previously
with IDEXX Laboratories, where she served as corporate vice
president, general counsel and secretary. In this role, she was
responsible for the legal, compliance and regulatory organizations
during the company's global expansion.
The full text announcement from Akili is as follows:
Akili Grows Leadership Team with Chief Financial Officer and
General Counsel Appointments
Santosh Shanbhag joins Akili as Chief Financial Officer
Jacqueline Studer joins Akili as Senior Vice President and
General Counsel
BOSTON, April 11, 2019 -- Akili Interactive ("Akili"), a leading
digital medicine company creating prescription treatments for
people living with cognitive dysfunction, today announced the
addition of two new executives to the Akili leadership team.
Santosh Shanbhag has been named Chief Financial Officer and
Jacqueline Studer has been named Senior Vice President and General
Counsel of Akili.
"Santosh and Jackie are talented executives whose extensive
business strategy and diverse industry experience make them the
perfect fit for our growing business," said Eddie Martucci, CEO of
Akili. "They bring tremendous financial and legal expertise to the
company which will help us continue to challenge the status quo of
medicine on our path to deliver new hope to patients living with
cognitive dysfunction."
Shanbhag is a senior financial executive with 20 years of
experience leading financial operations for US and international
organizations and executing complex business programs for
transformative healthcare companies. Prior to joining Akili,
Shanbhag held senior finance leadership roles at Vertex
Pharmaceuticals, most recently as Vice President and Head of
International Finance and Accounting where he helped build-out the
international business and secure reimbursement for novel medicines
in key international markets. Prior to Vertex, Shanbhag served in
positions of increasing responsibility at Capgemini Consulting and
Texas Instruments. He holds a MS in Management & Engineering
from MIT and Sloan School of Management, and an MS in Mechanical
Engineering from the University of Massachusetts, Amherst.
"I'm excited to be an Akilian and look forward to helping the
company scale and globalize its business as Akili delivers on its
promise to redefine medicine and the healthcare experience," said
Shanbhag.
Studer has decades of experience providing legal strategy and
support to large and emerging growth healthcare companies. Prior to
joining Akili, she served as Corporate Vice President, General
Counsel and Secretary at IDEXX Laboratories, where she led the
legal, compliance and regulatory organizations and was charged with
building a legal, privacy and regulatory organization and framework
to support the company's rapid global expansion. She held prior
roles leading the legal, privacy and compliance organizations at
Blue Health Intelligence, Allscripts Healthcare Solutions, and
various leadership positions at GE Healthcare including as General
Counsel of the GE Healthcare IT & Performance Solutions
division. Studer holds a bachelor's degree in management from
Purdue University and a JD from Columbia University School of
Law.
"With its engaging technology and ground-breaking science, Akili
has a unique opportunity to personalize the treatment of cognitive
dysfunction," said Studer. "I am honored to be a part of the Akili
team as we work to change how patients interact with their medicine
company."
About Akili
Akili is a leading digital medicine company combining scientific
and clinical rigor with the ingenuity of the tech industry to
reinvent medicine. Akili is pioneering the development of
prescription digital treatments with direct therapeutic activity,
delivered not through a pill but through a high-quality action
video game experience. Akili is advancing a broad pipeline of
programs to treat cognitive deficiency and improve symptoms
associated with medical conditions across neurology and psychiatry,
including attention-deficit/hyperactivity disorder, major
depressive disorder, autism spectrum disorder and various
inflammatory diseases. The Company is also developing complementary
and integrated clinical monitors and measurement-based care
applications. Akili was co-founded by PureTech Health (PRTC.L) and
is a founding member of the Digital Therapeutics Alliance. For more
information on Akili, please visit: www.akiliinteractive.com.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations. These statements are not
guarantees of future performance and undue reliance should not be
placed on them. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to,
and expressly disclaims any obligation to, update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep
insights into the connection between these systems and the
resulting role in diseases that have proven resistant to
established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech Health is developing new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions: its Affiliates and its Internal
labs. PureTech's Affiliates include seven clinical-stage platforms
with two product candidates that have been filed with the US Food
and Drug Administration (FDA) for review and other novel
pre-clinical programmes. These Affiliates are developing
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading experts.
PureTech's Internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations. These statements are not
guarantees of future performance and undue reliance should not be
placed on them. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to,
and expressly disclaims any obligation to, update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For more information, contact:
Contact:
Investors Akili Interactive
Allison Mead Talbot Julie DiCarlo
+1 617 651 3156 1-800-862-7807
amt@puretechhealth.com julie@akiliinteractive.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKBLFFKZFBBBV
(END) Dow Jones Newswires
April 11, 2019 08:00 ET (12:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024